PURE Bioscience Reports Fiscal 2021 Second Quarter And Six-Month Financial Results
RANCHO CUCAMONGA, Calif.--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter and six-month period ended January 31, 2021. Q2: Summary of Results of Operations Net product sales for the fiscal second quarter ended January 31, 2021 increased 149% to $868,000, compared to $349,000 for the fiscal second quarter ended January 31, 2020. The increase of $51
